Literature DB >> 26993054

Prenatal diagnosis of hemoglobinopathies in Tunisia: an 18 years of experience.

F Ouali1, H Siala1, A Bibi1, S Hadj Fredj1, B Dakhlaoui1, R Othmani1, F Ouenniche1, F Zouari2, B Bouguerra3, H Rezigua2, S Fattoum1, T Messaoud1.   

Abstract

UNLABELLED: Hemoglobinopathies are the most common genetic disease in Tunisia with a total carrier prevalence of 4.48%.
OBJECTIVE: The aim of this study was to report an 18-year fully achieved experience of prenatal diagnosis (PND) of hemoglobinopathies (1994-2012) and to assess the impact of this prevention program. PATIENT AND METHODS: A total of 461 fetuses of 340 at-risk couples have been the subject of PND for beta-thalassemia major risk (41%), for sickle cell anemia risk (40.3%), for S/beta-thal risk (14.7%). The remainder fetuses were at risk for a compound heterozygote hemoglobinopathies (S/O, O/beta-thal, S/C….). Fetal DNA was studied by PCR procedure including the reverse dot-blot technique and the amplification refractory mutation system and direct sequencing. RESULTS AND DISCUSSION: Only 13.8% of the fetal samplings were conducted by chorionic villus sampling. The molecular result for beta-thalassemia risk has shown 13 beta-thal mutations, with two common: codon 39 (C>T) and IVS1-110 (G>A). The last 3 years, STR study has permitted to reduce the problems of maternal cell contamination. Among the 461 tested fetuses, 121 were affected, and then the pregnancy was terminated except for 13 cases, because of religious considerations and this despite the abortion legality in Tunisia. The conducted PND is only about 30 PND per year corresponding essentially to the couples living in Tunis City and surrounding area. PND number has increased from 1994 to 2009. This evolution has brutally decreased after the Tunisian revolution (2010).
CONCLUSION: Although the good running of the PND, it covers only the Tunis city with low impact because it prevent apparition of only a mean of 7.3% of new cases. The reduced number of PND is not a technical inconvenience but rather a lack of a preventive program.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  Prenatal diagnosis; amniocentesis; beta-thalassemia; chorionic villus sampling; hemoglobinopathies; sickle cell disease

Mesh:

Year:  2016        PMID: 26993054     DOI: 10.1111/ijlh.12457

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN: 1751-5521            Impact factor:   2.877


  3 in total

1.  Genetics and genomic medicine in Tunisia.

Authors:  Houda Elloumi-Zghal; Habiba Chaabouni Bouhamed
Journal:  Mol Genet Genomic Med       Date:  2018-03       Impact factor: 2.183

2.  Spectrum of Genetic Diseases in Tunisia: Current Situation and Main Milestones Achieved.

Authors:  Nessrine Mezzi; Olfa Messaoud; Rahma Mkaouar; Nadia Zitouna; Safa Romdhane; Ghaith Abdessalem; Cherine Charfeddine; Faouzi Maazoul; Ines Ouerteni; Yosr Hamdi; Anissa Zaouak; Ridha Mrad; Sonia Abdelhak; Lilia Romdhane
Journal:  Genes (Basel)       Date:  2021-11-19       Impact factor: 4.096

3.  Use of an automated pyrosequencing technique for confirmation of sickle cell disease.

Authors:  Camila Cruz de Martino; Cecilia Salete Alencar; Paula Loureiro; Anna Barbara de Freitas Carneiro-Proietti; Claudia de Alvarenga Máximo; Rosimere Afonso Mota; Daniela Oliveira Werneck Rodrigues; Nelson Gaburo Junior; Shannon Kelly; Ester Cerdeira Sabino
Journal:  PLoS One       Date:  2019-12-12       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.